Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nimenrix + Boostrix
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Nimenrix + Boostrix refers to the co-administration of two distinct vaccines developed by GSK: Nimenrix, a quadrivalent meningococcal conjugate vaccine, and Boostrix, a reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) vaccine. Nimenrix is designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y by inducing bactericidal antibodies against their capsular polysaccharides. Boostrix is indicated for booster immunization against tetanus, diphtheria, and pertussis. Clinical studies have demonstrated that the simultaneous administration of these two vaccines at separate injection sites is immunogenic and well-tolerated in adolescents, with no significant interference in the immune response to any of the component antigens. This combination is a standard component of adolescent immunization schedules in many regions.
- Other names
- meningococcal group A, C, W-135, and Y conjugate vaccine + tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccineMenACWY-TT + Tdap
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)BCR (Immunoglobulin G B Cell Receptor)Neisseria meningitidis capsular polysaccharideCD4+ T-cell receptor (TCR) recognizing tetanus toxoid-derived peptidesTT (Tetanus toxoid)
Beyond the preview
Go deeper on Nimenrix + Boostrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimenrix + Boostrix.